---
document_datetime: 2023-09-21 17:23:19
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/axumin-epar-all-authorised-presentations_en.pdf
document_name: axumin-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.906061
conversion_datetime: 2025-12-28 00:30:44.806391
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Annex A

| MA (EU) number   | (Invented) name   | Strength    | Pharmaceutical Form    | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size       |
|------------------|-------------------|-------------|------------------------|---------------------------|-----------------------|---------------------------|-----------------|
| EU/1/17/1186/001 | Axumin            | 1600 MBq/ml | Solution for injection | Intravenous use           | vial (glass)          | 1.0 - 10 ml               | 1 vial of 10 ml |
| EU/1/17/1186/002 | Axumin            | 3200 MBq/ml | Solution for injection | Intravenous use           | vial (glass)          | 1.0 - 10 ml               | 1 vial of 10 ml |
| EU/1/17/1186/003 | Axumin            | 1600 MBq/ml | Solution for injection | Intravenous use           | vial (glass)          | 1.0 - 10 ml               | 1 vial of 15 ml |
| EU/1/17/1186/004 | Axumin            | 3200 MBq/ml | Solution for injection | Intravenous use           | vial (glass)          | 1.0 - 10 ml               | 1 vial of 15 ml |